Williams C K
Department of Haematology, College of Medicine, University of Ibadan, Nigeria.
Afr J Med Med Sci. 1987 Dec;16(4):163-9.
A review of some of the developments over the last two decades in the field of chemotherapy of the lymphomas is provided. The evolution of the current treatment regimens through clinical trials is emphasized, and the need to develop a similar approach to cancer chemotherapy in African treatment centres is advocated. In view of their different natural histories, non-Hodgkin's lymphoma (NHL) of 'favourable' and 'unfavourable' histologic variants need to be treated differently. While the former type of NHL need only a non-myelosuppressive chemotherapy, the latter would benefit from intensive chemotherapy involving the use of adriamycin and cytosine arabinoside, which appear to have salutary effects in this form of NHL. Burkitt's and Hodgkin's lymphomas are both highly curable forms of cancer and indications are given in support of further improvement in their current chemotherapeutic management. As over 50% of adequately treated lymphoma patients are likely to experience prolonged survival, more attention is now being directed to factors contributory to their quality of life. Thus, some complications of chemotherapy and their prevention are reviewed.
本文回顾了过去二十年淋巴瘤化疗领域的一些进展。强调了通过临床试验当前治疗方案的演变，并主张在非洲治疗中心采用类似的癌症化疗方法。鉴于其不同的自然病程，“预后良好”和“预后不良”组织学亚型的非霍奇金淋巴瘤（NHL）需要区别对待。前一种类型的NHL仅需非骨髓抑制性化疗，而后一种则可从使用阿霉素和阿糖胞苷的强化化疗中获益，这两种药物似乎对这种形式的NHL有有益作用。伯基特淋巴瘤和霍奇金淋巴瘤都是高度可治愈的癌症形式，并给出了支持进一步改善其当前化疗管理的指征。由于超过50%得到充分治疗的淋巴瘤患者可能会长期存活，现在更多的注意力正转向影响其生活质量的因素。因此，本文对化疗的一些并发症及其预防进行了综述。
